Bringing the fundamentals into focus…
Back to Pharming Group N.V.
How Pharming Group N.V. stacks up
PHAR · against 489 other Healthcare companies of similar size
Valuation
42/ 100
Below the middle of the pack.
Ranked #278 of 490 · scores higher than 43% of peers
Bars: peers in each 10-point band of the valuation score47 peers with a valuation score of 40–49, including PHAR · Click a bar to see the companies
Why valuation scores 42?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- Earnings yield is close to the peer norm. Earnings yield: 0.2% vs peer median 1.5%
- EBITDA yield is close to the peer norm. EBITDA yield: 3.8% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 72% of peers. Free cash flow yield: 2.9% vs peer median 0.0%
Metric by metric
Position: dot = PHAR, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PHAR | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 478 reported | 1.1% | 1.1% | 49% | 30% | |
| EBITDA yieldHigher is better · 496 reported | 3.8% | 4.0% | 49% | 50% | |
| Free cash flow yieldHigher is better · 211 reported | 3.8% | -2.6% | 78% | 20% | |
| Book yieldHigher is better · 487 reported | 29.5% | 41.5% | 32% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around PHARScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score